{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:17:27Z","timestamp":1791155847584,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1997,9]]},"DOI":"10.1212\/wnl.49.3.724","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:29:58Z","timestamp":1336915798000},"page":"724-728","source":"Crossref","is-referenced-by-count":222,"title":["Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease"],"prefix":"10.1212","volume":"49","author":[{"given":"K. M.","family":"Shannon","sequence":"first","affiliation":[{"name":"From the Department of Neurological Sciences (Dr. Shannon), Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL; Department of Neurology (Dr. Bennett), University of Virginia, Charlottesville, VA; and Department of Neurology (Dr. Friedman), Brown University, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"J. P.","family":"Bennett","sequence":"additional","affiliation":[{"name":"From the Department of Neurological Sciences (Dr. Shannon), Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL; Department of Neurology (Dr. Bennett), University of Virginia, Charlottesville, VA; and Department of Neurology (Dr. Friedman), Brown University, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Friedman","sequence":"additional","affiliation":[{"name":"From the Department of Neurological Sciences (Dr. Shannon), Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL; Department of Neurology (Dr. Bennett), University of Virginia, Charlottesville, VA; and Department of Neurology (Dr. Friedman), Brown University, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Pramipexole Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","first-page":"2","volume":"8","year":"1993","unstructured":"Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1993;8:263-270.","journal-title":"Mov Disord"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S6-S12.","DOI":"10.1212\/WNL.45.3_Suppl_3.S6"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90600-9"},{"key":"e_1_3_1_5_2","unstructured":"Lieberman A. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline. Neurology 1992;42(suppl 4):37-40."},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"Mizuno Y Kondo T Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(suppl 3):S13-S21.","DOI":"10.1212\/WNL.45.3_Suppl_3.S13"},{"key":"e_1_3_1_7_2","first-page":"8","volume":"37","year":"1987","unstructured":"Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.","journal-title":"Neurology"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","unstructured":"Wolters EC Tissingh G Bergmans PLM Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3): 528-534.","DOI":"10.1212\/WNL.45.3_Suppl_3.S28"},{"key":"e_1_3_1_9_2","first-page":"2","volume":"290","year":"1995","unstructured":"Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995;290:29-36.","journal-title":"Eur J Pharmacol"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198602000-00001"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Mov Disord 1994;4(suppl 1):S86-S94.","DOI":"10.1002\/mds.870040511"},{"key":"e_1_3_1_12_2","first-page":"3","volume":"18","year":"1995","unstructured":"Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_1_13_2","first-page":"4","volume":"17","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.","journal-title":"Neurology"},{"key":"e_1_3_1_14_2","unstructured":"Fahn S Elton RL Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S Marsden CD Goldstein M Calne DB eds. Recent developments in Parkinson's disease. New York: Macmillan 1987;153-163."},{"key":"e_1_3_1_15_2","first-page":"9","volume":"40","year":"1990","unstructured":"Boyce S, Rupniak NM, Steventon MJ, Iverson SD. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990;40:927-933.","journal-title":"Neurology"},{"key":"e_1_3_1_16_2","unstructured":"Alberts MJ Stajich J Olanow CW. A randomized blinded study of low-dose bromocriptine versus low-dose carbidopa\/levodopa in untreated Parkinson's patients. In: Fahn S Marsden CD Goldstein M Calne DB eds. Recent developments in Parkinson's disease. New York: Macmillan 1987:201-208."},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.Suppl.9"},{"key":"e_1_3_1_18_2","first-page":"5","volume":"14","year":"1987","unstructured":"Libman I, Gawel MJ, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of \"de novo\" Parkinson's disease patients. Can J Neurol Sci 1987;14:576-580.","journal-title":"Can J Neurol Sci"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.42.1.1"},{"key":"e_1_3_1_20_2","first-page":"2","volume":"36","year":"1986","unstructured":"Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, van der Burg W, Lakke JP. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 1986;36:291-293.","journal-title":"Neurology"},{"key":"e_1_3_1_21_2","first-page":"5","volume":"45","year":"1986","unstructured":"Stern G, Lees A. Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease. Adv Neurol 1986;45:525-527.","journal-title":"Adv Neurol"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198702000-00001"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.52.1.7"},{"key":"e_1_3_1_24_2","first-page":"5","volume":"45","year":"1987","unstructured":"van der Drift JHA. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study. Adv Neurol 1987;45:529-534.","journal-title":"Adv Neurol"},{"key":"e_1_3_1_25_2","first-page":"3","volume":"199","year":"1991","unstructured":"Taylor JR, Lawrence MS, Redmond DE, et al. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 1991;199:389-391.","journal-title":"Eur J Pharmacol"},{"key":"e_1_3_1_26_2","first-page":"2","volume":"267","year":"1993","unstructured":"Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.44.1.1"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.49.3.724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T15:40:01Z","timestamp":1711554001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.49.3.724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,9]]}},"alternative-id":["10.1212\/WNL.49.3.724"],"URL":"https:\/\/doi.org\/10.1212\/wnl.49.3.724","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,9]]}}}